Coulter posts losses in fiscal 1999
Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end
Radiopharmaceutical firm Coulter Pharmaceuticals reported losses for both the fourth quarter and fiscal year 1999 (end-December). The company posted quarter losses of $14.5 million, compared to net income of $25.5 million in 1998, and dramatic year-end losses of $50.6 million, compared to $2 million the year before. The South San Francisco, CA, company attributed these results to increased operating expenses to support its R&D and commercialization activities for Bexxar, the cancer therapy product Coulter is developing with SmithKline Beecham for the treatment of non-Hodgkins lymphoma. Coulter ended the year with cash assets of $82 million.
In other Coulter news, the firm has received a composition patent from the U.S. Patent and Trademark Office. Arising from Coulters work on Bexxar, the patent covers radiolabeled monoclonal antibodies for the treatment of B-cell lymphomas, and strengthens Coulters position in the field of radioimmunotherapy, according to president and CEO Michael Bigham.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
